• Beta Bionics posted a GAAP net loss of USD 23.4 million, widening 39% year over year for the quarter ended June 30, 2026.
• GAAP net sales climbed 38% to USD 32 million, driven by higher single-use product volumes tied to installed base growth.
• Gross margin improved 5 percentage points to 59%, reflecting increased production scale, lower warranty expense, improved cost absorption.
• Sales mix shifted toward pharmacy, with PBP channel at 36% of net sales versus 20% a year earlier on expanded PBM coverage.
• Cash, cash equivalents, short-term and long-term investments totaled USD 225.2 million as of June 30, 2026; funding runway projected through first half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-323777), on July 29, 2026, and is solely responsible for the information contained therein.